Μπιλαστίνη (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Μπιλαστίνη" in Greek language version.

refsWebsite

Global rank Greek rank

12nih.gov

4^th place

11doi.org

2^nd place

3^rd place

1medicines.org.uk

3,823^rd place

2,141^st place

1drugs.com

399^th place

130^th place

1archive.org

6^th place

5^th place

archive.org

«Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study». Clin. Exp. Allergy 39 (9): 1338–1347. 2009. doi:10.1111/j.1365-2222.2009.03257.x. PMID 19438584. https://archive.org/details/sim_clinical-and-experimental-allergy_2009-09_39_9/page/1338.

doi.org

dx.doi.org

«Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: Receptor selectivity and in vitro antihistaminic activity». Drugs in R&D 6 (6): 371–84. 2005. doi:10.2165/00126839-200506060-00005. PMID 16274260.
«Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review». Current Medical Research and Opinion 28 (1): 131–9. 2012. doi:10.1185/03007995.2011.648263. PMID 22149770.
«Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients». Allergy 64 (1): 158–65. 2009. doi:10.1111/j.1398-9995.2008.01813.x. PMID 19132976.
«Bilastine: a new H1 -antihistamine with an optimal profile for updosing in urticaria». J Eur Acad Dermatol Venereol 31 (9): 1447–1452. 2017. doi:10.1111/jdv.14305. PMID 28467671.
«Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study». Clin. Exp. Allergy 39 (9): 1338–1347. 2009. doi:10.1111/j.1365-2222.2009.03257.x. PMID 19438584. https://archive.org/details/sim_clinical-and-experimental-allergy_2009-09_39_9/page/1338.
«The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna challenge chamber». Inflamm. Res. 59 (5): 391–398. 2010. doi:10.1007/s00011-009-0117-4. PMID 19943178.
Bachert, C.; Kuna, P.; Zuberbier, T. (1 June 2010). «Bilastine in allergic rhinoconjunctivitis and urticaria». Allergy 65: 1–13. doi:10.1111/j.1398-9995.2010.02404.x.
«Fruit juice inhibition of uptake transport: a new type of food-drug interaction». Br. J. Clin. Pharmacol. 70 (5): 645–655. 2010. doi:10.1111/j.1365-2125.2010.03722.x. PMID 21039758.
«Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist. Receptor selectivity and in vitro antihistaminic activity». Drugs in R&D 6 (6): 371–384. 2005. doi:10.2165/00126839-200506060-00005. PMID 16274260.
«An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria». Expert Review of Clinical Immunology 8 (1): 33–41. 1 January 2012. doi:10.1586/eci.11.87. PMID 22149338.
«Pharmacokinetic-Pharmacodynamic Modelling of the Antihistaminic (H1) Effect of Bilastine». Clinical Pharmacokinetics 48 (8): 543–554. 1 August 2009. doi:10.2165/11317180-000000000-00000. PMID 19705924.

drugs.com

Bilastine Approval Status, drugs.com

medicines.org.uk

«Ilaxten 20 mg tablets - Summary of Product Characteristics (SmPC)». (emc). Ανακτήθηκε στις 16 Ιουνίου 2021.

nih.gov

ncbi.nlm.nih.gov

«Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: Receptor selectivity and in vitro antihistaminic activity». Drugs in R&D 6 (6): 371–84. 2005. doi:10.2165/00126839-200506060-00005. PMID 16274260.
«Bilastine and quality of life». Journal of Investigational Allergology and Clinical Immunology 21 Suppl 3: 16–23. 2011. PMID 22185046.
«Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review». Current Medical Research and Opinion 28 (1): 131–9. 2012. doi:10.1185/03007995.2011.648263. PMID 22149770.
«Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients». Allergy 64 (1): 158–65. 2009. doi:10.1111/j.1398-9995.2008.01813.x. PMID 19132976.
«Bilastine: a new H1 -antihistamine with an optimal profile for updosing in urticaria». J Eur Acad Dermatol Venereol 31 (9): 1447–1452. 2017. doi:10.1111/jdv.14305. PMID 28467671.
«Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study». Clin. Exp. Allergy 39 (9): 1338–1347. 2009. doi:10.1111/j.1365-2222.2009.03257.x. PMID 19438584. https://archive.org/details/sim_clinical-and-experimental-allergy_2009-09_39_9/page/1338.
«The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna challenge chamber». Inflamm. Res. 59 (5): 391–398. 2010. doi:10.1007/s00011-009-0117-4. PMID 19943178.
«Fruit juice inhibition of uptake transport: a new type of food-drug interaction». Br. J. Clin. Pharmacol. 70 (5): 645–655. 2010. doi:10.1111/j.1365-2125.2010.03722.x. PMID 21039758.
«Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist. Receptor selectivity and in vitro antihistaminic activity». Drugs in R&D 6 (6): 371–384. 2005. doi:10.2165/00126839-200506060-00005. PMID 16274260.
«An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria». Expert Review of Clinical Immunology 8 (1): 33–41. 1 January 2012. doi:10.1586/eci.11.87. PMID 22149338.
«Pharmacokinetic-Pharmacodynamic Modelling of the Antihistaminic (H1) Effect of Bilastine». Clinical Pharmacokinetics 48 (8): 543–554. 1 August 2009. doi:10.2165/11317180-000000000-00000. PMID 19705924.

pubmedcentral.nih.gov

«Fruit juice inhibition of uptake transport: a new type of food-drug interaction». Br. J. Clin. Pharmacol. 70 (5): 645–655. 2010. doi:10.1111/j.1365-2125.2010.03722.x. PMID 21039758.